450O Initial Monotherapy Results of a Phase I First-in-human Study of ULK1/2 Inhibitor DCC-3116 Alone and in Combination with MAPK Pathway Inhibition
Annals of Oncology（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined